Literature DB >> 19935710

A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.

Y Watanabe1, T Kojima, S Kagawa, F Uno, Y Hashimoto, S Kyo, H Mizuguchi, N Tanaka, H Kawamura, D Ichimaru, Y Urata, T Fujiwara.   

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-S/hep)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935710     DOI: 10.1038/onc.2009.415

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Controlling the Evolution of Resistance.

Authors:  Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski
Journal:  J Process Control       Date:  2011-03-01       Impact factor: 3.666

2.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

Review 3.  Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Authors:  Lukasz Kuryk; Giulia Rodella; Monika Staniszewska; Katarzyna Wanda Pancer; Magdalena Wieczorek; Stefano Salmaso; Paolo Caliceti; Mariangela Garofalo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.

Authors:  Masashi Kobayashi; Cheng-Long Huang; Makoto Sonobe; Ryutaro Kikuchi; Masashi Ishikawa; Jiro Kitamura; Ryo Miyahara; Toshi Menju; Shotaro Iwakiri; Kazumi Itoi; Ryoji Yasumizu; Hiroshi Date
Journal:  Exp Ther Med       Date:  2012-03-12       Impact factor: 2.447

Review 5.  Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma.

Authors:  Andrea Viti; Luca Bertolaccini; Alberto Terzi
Journal:  Ann Transl Med       Date:  2015-10

6.  Investigational approaches for mesothelioma.

Authors:  Veerle F Surmont; Eric R E van Thiel; Karim Vermaelen; Jan P van Meerbeeck
Journal:  Front Oncol       Date:  2011-08-22       Impact factor: 6.244

Review 7.  Emerging Roles of Heparanase in Viral Pathogenesis.

Authors:  Neel Thakkar; Tejabhiram Yadavalli; Dinesh Jaishankar; Deepak Shukla
Journal:  Pathogens       Date:  2017-09-18

Review 8.  A potential therapeutic strategy for malignant mesothelioma with gene medicine.

Authors:  Yuji Tada; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Biomed Res Int       Date:  2013-01-16       Impact factor: 3.411

Review 9.  Oncolytic virotherapy for human malignant mesothelioma: recent advances.

Authors:  Nicolas Boisgerault; Carole Achard; Tiphaine Delaunay; Laurent Cellerin; Frédéric Tangy; Marc Grégoire; Jean-François Fonteneau
Journal:  Oncolytic Virother       Date:  2015-09-10

Review 10.  Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Authors:  Samantha Turnbull; Emma J West; Karen J Scott; Elizabeth Appleton; Alan Melcher; Christy Ralph
Journal:  Viruses       Date:  2015-12-02       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.